

EARLIER DIAGNOSIS + EARLIER INTERVENTION = BETTER OUTCOMES

Research shows that the earlier a child receives an autism diagnosis, the better. Treatment can begin sooner, leading to better outcomes. While the average age for diagnosis of ASD is four years, the **NPDx ASD test** is for children as young as 18 months, and can identify about 63% of children with an increased risk of an ASD diagnosis.

WHAT IS THE NPDx ASD TEST?

- A new diagnostic tool to help children and families affected by autism spectrum disorder (ASD) that may lead to an earlier diagnosis for children with ASD.
- The **NPDx ASD test** can identify about 63% of children with an increased risk of an ASD diagnosis.
- It measures differences in metabolism of children with ASD compared to their neurotypical peers.
- Provides metabolic information that can help inform more precise treatment suggestions from doctors, based on information about their own metabolism.

WHO SHOULD GET THE TEST?

- is delayed in reaching developmental milestones (a possible indicator of ASD) as evaluated using tools such as MCHAT, ASQ-3, PEDS, STAT, etc.
- has failed screening for developmental milestones, indicating risk for autism spectrum disorder (ASD), such as M-CHAT, ASQ-3, PEDS, STAT, etc.
- has a family history, such as a sibling diagnosed with ASD
- already has an ASD diagnosis for whom additional metabolic information may provide insight into

IMPORTANT FACTS ABOUT THE TEST

- The test must be ordered by a physician, who will receive the results.
- There are specific sample collection and shipping instructions that must be followed. The

health care professionals who draw your child's blood should visit the NeuroPointDX website or call us for details.

- The test is not currently covered by insurance. Contact NeuroPointDX for details on price and financial assistance programs.

CLIA AND CAP ACCREDITED

- The NPDx ASD test is a lab-developed test (LDT) that was validated in a CLIA-accredited lab. CLIA, or Clinical Laboratory Improvement Amendments, sets standards for laboratory tests performed on human specimens, like blood, tissue, or saliva.
- NeuroPointDX's CLIA number is #52D2122420 and CAP (College of American Pathologists) number is #8674499.

REFERENCES

- Smith, et al. Amino acid dysregulation metabolotypes: Potential biomarkers for diagnosis and individualized treatment for subtypes of autism spectrum disorder. *Biological Psychiatry*, 2018; 85(4):345-354.
- Smith, et al. A metabolomics approach to screening for autism risk in the Children's Autism Metabolome Project. *Autism Research*, 2020; 13(8):1270-1285.

CONTACT US

NeuroPointDX is a Division of Stemina Biomarker Discovery, located in Madison, WI USA

<http://www.neuropointdx.com/>
contact@neuropointdx.com